21 and older, any sex, with Cancer or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Fatigue as Assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0-Fatigue 6aPrimary· Pre- and post-intervention, up to 12 weeks
Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v1.0-Fatigue 6a. This 6-item measure covers fatigue frequency, duration, intensity, and impact on daily activities. Responses were summed to generate a raw score (range 6-30), which was converted to a standardized T-score (mean = 50, SD = 10) based on the U.S. general population. Higher T-scores indicate greater fatigue (worse outcome). The reported outcome is the change in PROMIS Fatigue T-score from baseline to completion, where negative values indicate improvement.
Group
Value
95% CI
The iHBE Program Group
-1.61
± 6.75
Usual Care (Control Group)
4.26
± 7.95
Change in Resilience as Assessed by Connor-Davidson Resilience ScalePrimary· Pre- and post-intervention, up to 12 weeks
Resilience was assessed using the Connor-Davidson Resilience Scale (CD-RISC; 10 items). Each item is rated on a 5-point Likert scale (0 = not true at all to 4 = true nearly all the time). Raw scores are summed to produce a total score ranging from 0 to 40, with higher scores indicating greater resilience (better outcome). The reported outcome is the mean change in raw score, calculated as the score at the completion time point (12 weeks) minus the score at baseline. Positive values indicate improvement in resilience.
Group
Value
95% CI
The iHBE Program Group
0.00
± 4.97
Usual Care (Control Group)
0.89
± 6.41
Change in Physical Well BeingPrimary· Pre- and post-intervention, up to 12 weeks
Physical well-being was assessed using the 36-Item Short Form Health Survey (SF-36). The measure was derived from the physical functioning, role-physical, and bodily pain domains. Each domain is scored from 0 to 100, with higher scores indicating better physical health. The reported outcome is the mean change in the averaged domain scores from baseline to completion. Positive values indicate improvement in physical well-being.
Group
Value
95% CI
The iHBE Program Group
14.48
± 26.48
Usual Care (Control Group)
-2.83
± 17.67
Change in Mental Well BeingPrimary· Pre- and post-intervention, up to 12 weeks
Mental well-being was assessed using the 36-Item Short Form Health Survey (SF-36). The Mental Component Score was calculated as the average of relevant domains (vitality, social functioning, role limitations due to emotional health, and mental health). Each domain is scored from 0 to 100, and the average domain score was used to represent overall mental well-being. Higher scores indicate better mental health. The reported outcome is the mean change in the averaged raw score from baseline to completion. Positive values indicate an improvement in mental well-being.
Group
Value
95% CI
The iHBE Program Group
2.51
± 6.29
Usual Care (Control Group)
0.16
± 16.21
Physical ActivitySecondary· 12 weeks
The physical activity will be measured in a form of average step count/day measured by a wrist-worn wearable device.
Group
Value
95% CI
The iHBE Program Group
1279.11
± 2986.71
Usual Care (Control Group)
805.46
± 1682.42
Sponsor's own description
A home-based, tailored, technology-enhanced home-based exercise program (iHBE) using a combination of the integrated mobile technologies (wearable device and phone application) and tailored home-based exercise will be pilot tested. Participants will choose one of the four home-based exercise options \[National Institute of Aging (NIA) Go4Life (an exercise and physical activity campaign from the NIA), Iyengar-style yoga, walking, and modified Otago exercise\] based on participants' preference and goals. The integrated mobile technologies system will allow the investigators to extract heart rate data directly from the wearable device to the research server. This data will be used to provide appropriate and personalized feedback on physical performance. The survey and notification to the participants on the smartphone.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors
· NA
· recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy
· NA
· recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients.
· NA
· recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations
· NA
· recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
· NA
· recruiting
Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials
Trials by the same sponsor.
NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
· Phase 1
· not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+
· Phase 2
· not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors
· NA
· not yet recruiting
NCT07140315 — DK222 Study at Hopkins
· Phase 1
· recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove
· EARLY_PHASE1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 14 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03874754.